NFE2L2 and hepatocellular carcinoma: Inhibition of NRF2 expression either by genetic tools or drugs significantly enhanced the antitumor effects of erastin and sorafenib in HCC, while activation of NRF2 expression resulted in hepatocellular carcinoma resistance to ferroptosis (121).